{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:03:57Z","timestamp":1793048637841,"version":"4.5.0"},"reference-count":39,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["U54GM104942"],"award-info":[{"award-number":["U54GM104942"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Colorectal cancer ranks third among the most commonly diagnosed cancers in the United States. Current therapies have a range of side effects, and the development of a reliable animal model to speed the discovery of safe effective preventative therapies would be of great value. A cross-sectional study in a large Appalachian population recently showed an association between low circulating levels of perfluorooctane sulfonate (PFOS) and a reduced prevalence of colorectal cancer. A study using APC<jats:sub>min<\/jats:sub> (C57BL\/6J-Apc<jats:sup>Min<\/jats:sup>\/J) mice prone to familial adenomatous polyposis found PFOS was protective when exposure occurred during tumor development. To test the possible benefit of PFOS on spontaneous colorectal cancer, we developed a mouse model utilizing primary patient colorectal cancer implants into NSG (NOD.Cg-<jats:italic>Prkdc<jats:sup>scid<\/jats:sup>Il2rg<jats:sup>tm1Wjl<\/jats:sup><\/jats:italic>\/Sz) mice. Study goals included: (1) to assess potential factors supporting the successful use of colorectal cancer from heterogeneous tumors for PDX studies; and, (2) evaluate PFOS as a therapy in tumor matched pairs of mice randomized to receive PFOS or vehicle. The time in days for mice to grow primary tumors to 5 mm took almost 2 months (mean = 53.3, se = 5.7, range = 17\u2013136). Age of mice at implantation, patient age, gender and race appeared to have no discernable effect on engraftment rates. Engraftment rates for low and high-grade patient tumors were similar. PFOS appeared to reduce tumor size dramatically in one group of tumors, those from the right ascending colon. That is, by 5 weeks of treatment in two mice, PFOS had eliminated their 52.4 mm<jats:sup>3<\/jats:sup> and 124.6 mm<jats:sup>3<\/jats:sup> masses completely, an effect that was sustained for 10 weeks of treatment; in contrast, their corresponding matched vehicle control mice had tumors that grew to 472.7 mm<jats:sup>3<\/jats:sup> and 340.1 mm<jats:sup>3<\/jats:sup> in size respectively during the same period. In a third xenograft mouse, the tumor growth was dramatically blunted although not eliminated, and compared favorably to their matched vehicle controls over the same period. These preliminary findings suggested that this mouse model may be advantageous for testing compounds of potential value in the treatment of colorectal cancer, and PFOS may have utility in selected cases.<\/jats:p>","DOI":"10.7717\/peerj.5602","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T08:36:54Z","timestamp":1541147814000},"page":"e5602","source":"Crossref","is-referenced-by-count":11,"title":["Assessment of a mouse xenograft model of primary colorectal cancer with special reference to perfluorooctane sulfonate"],"prefix":"10.7717","volume":"6","author":[{"given":"Jeffrey H.","family":"Wimsatt","sequence":"first","affiliation":[{"name":"Department of Medicine, West Virginia University, Morgantown, WV, United States of America"},{"name":"Department of Epidemiology, West Virginia University, Morgantown, WV, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Department of Medicine, West Virginia University, Morgantown, WV, United States of America"},{"name":"Department of Epidemiology, West Virginia University, Morgantown, WV, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel S.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Medicine, West Virginia University, Morgantown, WV, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charity","family":"Savard","sequence":"additional","affiliation":[{"name":"Department of Medicine, West Virginia University, Morgantown, WV, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Tallman","sequence":"additional","affiliation":[{"name":"Department of Medicine, West Virginia University, Morgantown, WV, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Innes","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, West Virginia University, Morgantown, WV, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nezar","family":"Jrebi","sequence":"additional","affiliation":[{"name":"Department of Surgery, West Virginia University, Morgantown, WV, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"key":"10.7717\/peerj.5602\/ref-1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1476-4598-7-94","article-title":"Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers","volume":"7","author":"Ahlquist","year":"2008","journal-title":"Molecular Cancer"},{"key":"10.7717\/peerj.5602\/ref-2","first-page":"1","volume-title":"Colorectal cancer","author":"American Cancer Society","year":"2017"},{"key":"10.7717\/peerj.5602\/ref-3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.tox.2006.08.004","article-title":"Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys\u2014probing the determinants of long plasma half-lives","volume":"227","author":"Andersen","year":"2006","journal-title":"Toxicology"},{"key":"10.7717\/peerj.5602\/ref-4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.yrtph.2016.11.021","article-title":"Carcinogenic risk of emerging persistent organic pollutant perfluorooctane sulfonate (PFOS): a proposal of classification","volume":"83","author":"Arrieta-Cortes","year":"2017","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"10.7717\/peerj.5602\/ref-5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/2159-8290.cd-11-0109","article-title":"A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","volume":"1","author":"Bertotti","year":"2011","journal-title":"Cancer Discovery"},{"key":"10.7717\/peerj.5602\/ref-6","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1053\/j.gastro.2011.06.039","article-title":"BCL9-2 promotes early stages of intestinal tumor progression","volume":"141","author":"Brembeck","year":"2011","journal-title":"Gastroenterology"},{"key":"10.7717\/peerj.5602\/ref-7","doi-asserted-by":"publisher","first-page":"66212","DOI":"10.18632\/oncotarget.11184","article-title":"Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review","volume":"7","author":"Brown","year":"2016","journal-title":"Oncotarget"},{"key":"10.7717\/peerj.5602\/ref-8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/ieam.258","article-title":"Perfluoroalkyl and polyfluoroalkyl substances in the environment: terminology, classification, and origins","volume":"7","author":"Buck","year":"2011","journal-title":"Integrated Environmental Assessment and Management"},{"key":"10.7717\/peerj.5602\/ref-9","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1289\/ehp.9060","article-title":"The applicability of biomonitoring data for perfluorooctanesulfonate to the environmental public health continuum","volume":"114","author":"Butenhoff","year":"2006","journal-title":"Environmental Health Perspectives"},{"key":"10.7717\/peerj.5602\/ref-10","article-title":"Colorectal (Colon) cancer statistics","author":"Centers for Disease Control and Prevention (CDC)","year":"2013"},{"issue":"Suppl 1","key":"10.7717\/peerj.5602\/ref-11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10408444.2014.905767","article-title":"A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and cancer risk in humans","volume":"44","author":"Chang","year":"2014","journal-title":"Critical Reviews in Toxicology"},{"key":"10.7717\/peerj.5602\/ref-12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.reprotox.2011.07.002","article-title":"Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys","volume":"33","author":"Chang","year":"2012","journal-title":"Reproductive Toxicology"},{"key":"10.7717\/peerj.5602\/ref-13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/0008-5472.can-06-0594","article-title":"Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features","volume":"67","author":"Dangles-Marie","year":"2007","journal-title":"Cancer Research"},{"key":"10.7717\/peerj.5602\/ref-14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jhazmat.2014.03.045","article-title":"Enhanced adsorption of perfluorooctane sulfonate and perfluorooctanoate by bamboo-derived granular activated carbon","volume":"282","author":"Deng","year":"2015","journal-title":"Journal of Hazardous Materials"},{"key":"10.7717\/peerj.5602\/ref-15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/10408440802209804","article-title":"Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha","volume":"39","author":"DeWitt","year":"2009","journal-title":"Critical Reviews in Toxicology"},{"key":"10.7717\/peerj.5602\/ref-16","article-title":"Technical fact sheet\u2014Perfluorooctane Sulfonate (PFOS) and Perfluorooctanoic Acid (PFOA)","author":"Environmental Protection Agency (EPA)","year":"2017"},{"key":"10.7717\/peerj.5602\/ref-17","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1158\/1078-0432.ccr-13-3047","article-title":"Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment","volume":"20","author":"Garralda","year":"2014","journal-title":"Clinical Cancer Research"},{"key":"10.7717\/peerj.5602\/ref-18","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1715053","article-title":"Tumor take rate optimization for colorectal carcinoma patient-derived xenograft models","author":"Gock","year":"2016"},{"key":"10.7717\/peerj.5602\/ref-19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1097\/JOM.0b013e3180582043","article-title":"Self-reported medical conditions in perfluorooctanesulfonyl fluoride manufacturing workers","volume":"49","author":"Grice","year":"2007","journal-title":"Journal of Occupational & Environmental Medicine"},{"key":"10.7717\/peerj.5602\/ref-20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0029-1242458","article-title":"Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors","volume":"22","author":"Haggar","year":"2009","journal-title":"Clinics in Colon and Rectal Surgery"},{"key":"10.7717\/peerj.5602\/ref-21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2407-14-45","article-title":"Inverse association of colorectal cancer prevalence to serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in a large Appalachian population","volume":"14","author":"Innes","year":"2014","journal-title":"BMC Cancer"},{"key":"10.7717\/peerj.5602\/ref-22","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3224","article-title":"Stromal contribution to the colorectal cancer transcriptome","author":"Isella","year":"2015"},{"key":"10.7717\/peerj.5602\/ref-23","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1158\/1078-0432.ccr-12-0372","article-title":"Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer","volume":"18","author":"Julien","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.7717\/peerj.5602\/ref-24","first-page":"240","article-title":"Mouse models for colorectal cancer","volume":"3","author":"Karim","year":"2013","journal-title":"American Journal of Cancer Research"},{"key":"10.7717\/peerj.5602\/ref-25","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.3748\/wjg.v20.i14.3835","article-title":"Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer","volume":"20","author":"Kim","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.7717\/peerj.5602\/ref-26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/1471-2407-10-362","article-title":"Cryopreservation of human colorectal carcinomas prior to xenografting","volume":"10","author":"Linnebacher","year":"2010","journal-title":"BMC Cancer"},{"key":"10.7717\/peerj.5602\/ref-27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1479-5876-10-125","article-title":"Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue","volume":"10","author":"Monsma","year":"2012","journal-title":"Journal of Translational Medicine"},{"key":"10.7717\/peerj.5602\/ref-28","doi-asserted-by":"publisher","first-page":"16059","DOI":"10.18632\/oncotarget.3863","article-title":"Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients","volume":"6","author":"Oh","year":"2015","journal-title":"Oncotarget"},{"key":"10.7717\/peerj.5602\/ref-29","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1289\/ehp.10009","article-title":"Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers","volume":"115","author":"Olsen","year":"2007","journal-title":"Environmental Health Perspectives"},{"key":"10.7717\/peerj.5602\/ref-30","doi-asserted-by":"publisher","first-page":"e0163521","DOI":"10.1371\/journal.pone.0163521","article-title":"NSG mice provide a better spontaneous model of breast cancer metastasis than athymic (Nude) mice","volume":"11","author":"Puchalapalli","year":"2016","journal-title":"PLOS ONE"},{"key":"10.7717\/peerj.5602\/ref-31","doi-asserted-by":"publisher","first-page":"6787","DOI":"10.1158\/1078-0432.ccr-12-1740","article-title":"A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells","volume":"19","author":"Puig","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.7717\/peerj.5602\/ref-32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4255\/mcpharmacol.09.05","article-title":"Anti-inflammatory agents for cancer therapy","volume":"1","author":"Rayburn","year":"2009","journal-title":"Molecular and Cellular Pharmacology"},{"issue":"Suppl 3","key":"10.7717\/peerj.5602\/ref-33","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0305-7372(10)70012-8","article-title":"Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer","volume":"36","author":"Sartore-Bianchi","year":"2010","journal-title":"Cancer Treatment Reviews"},{"key":"10.7717\/peerj.5602\/ref-34","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1101\/pdb.top073585","article-title":"Human cancer growth and therapy in immunodeficient mouse models","volume":"2014","author":"Shultz","year":"2014","journal-title":"Cold Spring Harbor Protocols"},{"key":"10.7717\/peerj.5602\/ref-35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/toxsci\/kfl135","article-title":"Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta\/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate","volume":"95","author":"Takacs","year":"2007","journal-title":"Toxicological Sciences"},{"key":"10.7717\/peerj.5602\/ref-36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.toxlet.2007.12.007","article-title":"Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis","volume":"177","author":"Tan","year":"2008","journal-title":"Toxicology Letters"},{"key":"10.7717\/peerj.5602\/ref-37","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/gut.2007.136127","article-title":"Guidelines for the clinical management of familial adenomatous polyposis (FAP)","volume":"57","author":"Vasen","year":"2008","journal-title":"Gut"},{"key":"10.7717\/peerj.5602\/ref-38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mrgentox.2013.04.004","article-title":"PFOS-induced apoptosis through mitochondrion-dependent pathway in human-hamster hybrid cells","volume":"754","author":"Wang","year":"2013","journal-title":"Mutation Research\/DNA Repair"},{"key":"10.7717\/peerj.5602\/ref-39","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1186\/s12885-016-2861-5","article-title":"Oral perfluorooctane sulfonate (PFOS) lessens tumor development in the APC(min) mouse model of spontaneous familial adenomatous polyposis","volume":"16","author":"Wimsatt","year":"2016","journal-title":"BMC Cancer"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/5602.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/5602.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/5602.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/5602.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T08:36:59Z","timestamp":1541147819000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/5602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":39,"alternative-id":["10.7717\/peerj.5602"],"URL":"https:\/\/doi.org\/10.7717\/peerj.5602","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]},"article-number":"e5602"}}